Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU7-159P is a non-coding RNA pseudogene annotated in the human genome. It is homologous to the functional U7 small nuclear RNA (U7 snRNA), which is involved in processing histone pre-mRNA as part of the U7 small nuclear ribonucleoprotein (snRNP) complex[5][7]. However, as a pseudogene designated "159," RNU7-159P is presumed nonfunctional—it does not encode a functional RNA product and is not known to be transcribed or biologically active in any tissue[2][8]. Pseudogenes in general are DNA sequences that resemble functional genes but have lost their protein-coding or RNA activity due to mutations or genomic rearrangements[8]. Unlike the functional RNU7-1 gene, whose disruption is associated with Aicardi-Goutières syndrome[1], RNU7-159P has no documented disease association or molecular function. It is included in genome annotations for completeness but does not represent a valid drug target, biomarker, or therapeutic entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U7 small nuclear 159 pseudogene (RNU7-159P).